Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 51
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Zhejiang Univ Sci B ; 22(12): 1034-1044, 2021 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-34904415

RESUMEN

Apolipoprotein A-I (ApoA-I), the main protein component of high-density lipoprotein (HDL), plays a pivotal role in reverse cholesterol transport (RCT). Previous studies indicated a reduction of serum ApoA-I levels in various types of cancer, suggesting ApoA-I as a potential cancer biomarker. Herein, ectopically overexpressed ApoA-I in MDA-MB-231 breast cancer cells was observed to have antitumor effects, inhibiting cell proliferation and migration. Subsequent studies on the mechanism of expression regulation revealed that estradiol (E2)/estrogen receptor α (ERα) signaling activates ApoA-I gene transcription in breast cancer cells. Mechanistically, our ChIP-seq data showed that ERα directly binds to the estrogen response element (ERE) site within the ApoA-I gene and establishes an acetylation of histone 3 lysine 27 (H3K27ac)|-enriched chromatin microenvironment. Conversely, Fulvestrant (ICI 182780) treatment blocked ERα binding to ERE within the ApoA-I gene and downregulated the H3K27ac level on the ApoA-I gene. Treatment with p300 inhibitor also significantly decreased the ApoA-I messenger RNA (mRNA) level in MCF7 cells. Furthermore, the analysis of data from The Cancer Genome Atlas (TCGA) revealed a positive correlation between ERα and ApoA-I expression in breast cancer tissues. Taken together, our study not only revealed the antitumor potential of ApoA-I at the cellular level, but also found that ERα promotes the transcription of ApoA-I gene through direct genomic effects, and p300 may act as a co-activator of ERα in this process.


Asunto(s)
Apolipoproteína A-I/genética , Neoplasias de la Mama/metabolismo , Cromatina/metabolismo , Receptor alfa de Estrógeno/fisiología , Genes Supresores de Tumor/fisiología , Microambiente Tumoral , Acetilación , Apolipoproteína A-I/fisiología , Neoplasias de la Mama/genética , Línea Celular Tumoral , Proteína p300 Asociada a E1A/fisiología , Exones , Femenino , Histonas/metabolismo , Humanos
2.
World Neurosurg ; 154: e566-e571, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-34314911

RESUMEN

BACKGROUND: Sevoflurane (Sev) is a rapidly acting, potent inhalation anesthetic with rapid uptake and elimination. But many studies have shown that Sev could result in cognition dysfunction in adolescent or aging patients. Now, therapeutic targeting with IL-17A antibody has shown a promising effect on Sev-induced cognition impairment. In the study we report that P300 inhibition could act as an alternative approach to decrease IL-17A activity. METHODS: SHSY5Y cells were treated with Sev and cell apoptosis was evaluated by Annexin V-FITC/PI staining. The expression of P300 and IL-17A were assessed by Western blotting. Water maze tests were conducted in order to assess the cognitive function. RESULTS: We found that P300 and IL-17A were activated in SHSY5Y cells treated with Sev. P300 inhibitor C646 could reduce the apoptosis induced by Sev through decreasing IL-17A avtivity. Furthermore, IL-17A expression was upregulated after neurons were transfected with P300 expression plasmid and IL-17A expression was downregulated after neurons were incubated with P300 inhibitor C646. P300 overexpression could upregulate the promoter activity of IL-17A. Finally, in a rat model treated with Sev, we also found C646 to significantly improve the cognition impairment through the IL-17A pathway. CONCLUSIONS: These data show that P300 will potentially be a new drug target for the therapy of cognition impairment caused by Sev.


Asunto(s)
Anestésicos por Inhalación/administración & dosificación , Apoptosis/efectos de los fármacos , Disfunción Cognitiva/inducido químicamente , Disfunción Cognitiva/prevención & control , Proteína p300 Asociada a E1A/antagonistas & inhibidores , Proteína p300 Asociada a E1A/fisiología , Interleucina-17/metabolismo , Sevoflurano/administración & dosificación , Línea Celular Tumoral , Humanos
3.
J Cell Mol Med ; 24(18): 10512-10524, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32691935

RESUMEN

Dysregulation of long non-coding RNAs (lncRNAs) has been implicated in many cancer developments. Previous studies showed that lncRNA LINC00941 was aberrantly expressed in oral squamous cell carcinoma (OSCC). However, its role in OSCC development remains elusive. In this study, we demonstrated that in OSCC cells, EP300 activates LINC00941 transcription through up-regulating its promoter H3K27ac modification. Up-regulated LINC00941 in turn activates CAPRIN2 expression by looping to CAPRIN2 promoter. Functional assays suggest that both LINC00941 and CAPRIN2 play pivotal roles in promoting OSCC cell proliferation and colony formation. In vivo assay further confirmed the role of LINC00941 in promoting OSCC cell tumour formation. Lastly, we showed that the role of LINC00941 and CAPRIN2 in OSCC progression was mediated through activating the canonical WNT/ß-catenin signaling pathway. Thus, LINC00941/CAPRIN2/ WNT/ß-catenin signaling pathway provides new therapeutic targets for OSCC treatment.


Asunto(s)
Carcinoma de Células Escamosas/patología , Neoplasias de la Boca/patología , Proteínas de Neoplasias/fisiología , ARN Largo no Codificante/metabolismo , ARN Neoplásico/fisiología , Proteínas de Unión al ARN/fisiología , Vía de Señalización Wnt/fisiología , Animales , Sistemas CRISPR-Cas , Carcinoma de Células Escamosas/genética , División Celular , Células Cultivadas , ADN de Neoplasias/genética , ADN de Neoplasias/ultraestructura , Progresión de la Enfermedad , Proteína p300 Asociada a E1A/fisiología , Regulación Neoplásica de la Expresión Génica , Genes Reporteros , Código de Histonas , Queratinocitos , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Neoplasias de la Boca/genética , Proteínas de Neoplasias/biosíntesis , Proteínas de Neoplasias/genética , Trasplante de Neoplasias , Regiones Promotoras Genéticas/genética , ARN Guía de Kinetoplastida/administración & dosificación , ARN Guía de Kinetoplastida/genética , ARN Largo no Codificante/genética , ARN Neoplásico/biosíntesis , ARN Neoplásico/genética , Proteínas de Unión al ARN/biosíntesis , Proteínas de Unión al ARN/genética , Proteínas Recombinantes/metabolismo , Ensayo de Tumor de Célula Madre , Regulación hacia Arriba , Vía de Señalización Wnt/genética
4.
J Biol Chem ; 294(51): 19667-19682, 2019 12 20.
Artículo en Inglés | MEDLINE | ID: mdl-31744881

RESUMEN

Estrogen and its cognate receptor, ERα, regulate cell proliferation, differentiation, and carcinogenesis in the endometrium by controlling gene transcription. ERα requires co-activators to mediate transcription via mechanisms that are largely uncharacterized. Herein, using growth-regulating estrogen receptor binding 1 (GREB1) as an ERα target gene in Ishikawa cells, we demonstrate that nuclear receptor co-activator 6 (NCOA6) is essential for estradiol (E2)/ERα-activated GREB1 transcription. We found that NCOA6 associates with the GREB1 promoter and enhancer in an E2-independent manner and that NCOA6 knockout reduces chromatin looping, enhancer-promoter interactions, and basal GREB1 expression in the absence of E2. In the presence of E2, ERα bound the GREB1 enhancer and also associated with its promoter, and p300, myeloid/lymphoid or mixed-lineage leukemia protein 4 (MLL4), and RNA polymerase II were recruited to the GREB1 enhancer and promoter. Consequently, the levels of the histone modifications H3K4me1/3, H3K9ac, and H3K27ac were significantly increased; enhancer and promoter regions were transcribed; and GREB1 mRNA was robustly transcribed. NCOA6 knockout reduced ERα recruitment and abolished all of the aforementioned E2-induced events, making GREB1 completely insensitive to E2 induction. We also found that GREB1-deficient Ishikawa cells are much more resistant to chemotherapy and that human endometrial cancers with low GREB1 expression predict poor overall survival. These results indicate that NCOA6 has an essential role in ERα-mediated transcription by increasing enhancer-promoter interactions through chromatin looping and by recruiting RNA polymerase II and the histone-code modifiers p300 and MLL4. Moreover, GREB1 loss may predict chemoresistance of endometrial cancer.


Asunto(s)
Elementos de Facilitación Genéticos , Receptor alfa de Estrógeno/fisiología , Estrógenos/farmacología , Proteínas de Neoplasias/fisiología , Coactivadores de Receptor Nuclear/fisiología , Regiones Promotoras Genéticas , Antineoplásicos/farmacología , Diferenciación Celular , Línea Celular Tumoral , Proliferación Celular , Resistencia a Antineoplásicos , Proteína p300 Asociada a E1A/fisiología , Receptor alfa de Estrógeno/genética , Femenino , Eliminación de Gen , Regulación Neoplásica de la Expresión Génica , N-Metiltransferasa de Histona-Lisina/fisiología , Histonas/química , Humanos , Proteína de la Leucemia Mieloide-Linfoide/fisiología
5.
Hum Mol Genet ; 28(1): 16-30, 2019 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-30215740

RESUMEN

Polycystin-1 (PC1), encoded by the PKD1 gene that is mutated in the autosomal dominant polycystic kidney disease, regulates a number of processes including bone development. Activity of the transcription factor RunX2, which controls osteoblast differentiation, is reduced in Pkd1 mutant mice but the mechanism governing PC1 activation of RunX2 is unclear. PC1 undergoes regulated cleavage that releases its C-terminal tail (CTT), which translocates to the nucleus to modulate transcriptional pathways involved in proliferation and apoptosis. We find that the cleaved CTT of PC1 (PC1-CTT) stimulates the transcriptional coactivator TAZ (Wwtr1), an essential coactivator of RunX2. PC1-CTT physically interacts with TAZ, stimulating RunX2 transcriptional activity in pre-osteoblast cells in a TAZ-dependent manner. The PC1-CTT increases the interaction between TAZ and RunX2 and enhances the recruitment of the p300 transcriptional co-regulatory protein to the TAZ/RunX2/PC1-CTT complex. Zebrafish injected with morpholinos directed against pkd1 manifest severe bone calcification defects and a curly tail phenotype. Injection of messenger RNA (mRNA) encoding the PC1-CTT into pkd1-morphant fish restores bone mineralization and reduces the severity of the curly tail phenotype. These effects are abolished by co-injection of morpholinos directed against TAZ. Injection of mRNA encoding a dominant-active TAZ construct is sufficient to rescue both the curly tail phenotype and the skeletal defects observed in pkd1-morpholino treated fish. Thus, TAZ constitutes a key mechanistic link through which PC1 mediates its physiological functions.


Asunto(s)
Desarrollo Óseo/genética , Péptidos y Proteínas de Señalización Intracelular/fisiología , Canales Catiónicos TRPP/fisiología , Animales , Apoptosis , Desarrollo Óseo/fisiología , Diferenciación Celular , Proteína p300 Asociada a E1A/fisiología , Regulación de la Expresión Génica , Genes Reguladores , Células HEK293 , Humanos , Riñón/metabolismo , Modelos Animales , Morfolinos , Osteoblastos/metabolismo , Osteogénesis/fisiología , Riñón Poliquístico Autosómico Dominante/genética , Canales Catiónicos TRPP/genética , Transactivadores , Factores de Transcripción , Proteínas Coactivadoras Transcripcionales con Motivo de Unión a PDZ , Pez Cebra/genética , Proteínas de Pez Cebra/genética
6.
Int J Cancer ; 143(4): 897-906, 2018 08 15.
Artículo en Inglés | MEDLINE | ID: mdl-29536528

RESUMEN

Prostate cancer (PCa) is the most common cancer among men. Metabolic syndrome (MeS) is associated with increased PCa aggressiveness and recurrence. Previously, we proposed C-terminal binding protein 1 (CTBP1), a transcriptional co-repressor, as a molecular link between these two conditions. Notably, CTBP1 depletion decreased PCa growth in MeS mice. The aim of this study was to investigate the molecular mechanisms that explain the link between MeS and PCa mediated by CTBP1. We found that CTBP1 repressed chloride channel accessory 2 (CLCA2) expression in prostate xenografts developed in MeS animals. CTBP1 bound to CLCA2 promoter and repressed its transcription and promoter activity in PCa cell lines. Furthermore, we found that CTBP1 formed a repressor complex with ZEB1, EP300 and HDACs that modulates the CLCA2 promoter activity. CLCA2 promoted PCa cell adhesion inhibiting epithelial-mesenchymal transition (EMT) and activating CTNNB1 together with epithelial marker (CDH1) induction, and mesenchymal markers (SNAI2 and TWIST1) repression. Moreover, CLCA2 depletion in PCa cells injected subcutaneously in MeS mice increased the circulating tumor cells foci compared to control. A microRNA (miRNA) expression microarray from PCa xenografts developed in MeS mice, showed 21 miRNAs modulated by CTBP1 involved in angiogenesis, extracellular matrix organization, focal adhesion and adherents junctions, among others. We found that miR-196b-5p directly targets CLCA2 by cloning CLCA2 3'UTR and performing reporter assays. Altogether, we identified a new molecular mechanism to explain PCa and MeS link based on CLCA2 repression by CTBP1 and miR-196b-5p molecules that might act as key factors in the progression onset of this disease.


Asunto(s)
Oxidorreductasas de Alcohol/fisiología , Adhesión Celular/fisiología , Canales de Cloruro/genética , Proteínas de Unión al ADN/fisiología , Proteína p300 Asociada a E1A/fisiología , Epigénesis Genética , Transición Epitelial-Mesenquimal/fisiología , Histona Desacetilasas/fisiología , Síndrome Metabólico/complicaciones , MicroARNs/fisiología , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/patología , Homeobox 1 de Unión a la E-Box con Dedos de Zinc/fisiología , Animales , Línea Celular Tumoral , Regulación Neoplásica de la Expresión Génica , Xenoinjertos , Humanos , Masculino , Ratones , Regiones Promotoras Genéticas , Neoplasias de la Próstata/complicaciones , Transcripción Genética
7.
Biochim Biophys Acta Gen Subj ; 1862(3): 474-484, 2018 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-29111275

RESUMEN

BACKGROUND: Morphine is used as an analgesic although it causes important secondary effects. These effects are triggered by several mechanisms leading to the dysregulation of gene expression. Here we aimed to study these alterations on neural stem cells (NSC) during CNS development. METHODS: AB strain and tg nestin:GFP zebrafish embryos, zebrafish primary neuron culture and mouse embryonic stem cells were used to assess the effect of morphine by qPCR, time lapse microscopy and western blot. ChIP-qPCR and bisulfite conversion assay were performed to determine the changes exerted by morphine in a Nestin candidate enhancer. RESULTS: Morphine increases GFP in nestin:GFP embryos and overexpresses the NSC marker Nestin. Morphine also exerts a hyperacetylation effect on H3K27 and decreases DNA methylation within a region located 18 Kb upstream nestin transcription starting site. Here, a binding site for the transcription factor complex Sox2/Oct4/Nanog was predicted. These factors are also upregulated by morphine. Besides, morphine increases the histone acetyl transferase p300. The inhibition of p300 activity decreases Nestin. CONCLUSIONS: Morphine facilitates Nestin increase by several mechanisms which include hyperacetylation of H3K27, decreased DNA methylation and the overexpression of the transcription factors sox2, oct4 and nanog. It has also been demonstrated that nestin levels depend on p300 activity. The facilitated Nestin expression delays the normal differentiation of neural stem cells. GENERAL SIGNIFICANCE: The present work provides novel evidence of the effects induced by morphine in the normal differentiation of NSCs, altering Nestin through changes on p300, H3K27ac, DNA methylation and Oct4, Sox2, and Nanog.


Asunto(s)
Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Morfina/farmacología , Nestina/biosíntesis , Células-Madre Neurales/efectos de los fármacos , Neurogénesis/efectos de los fármacos , Proteínas de Pez Cebra , Acetilación/efectos de los fármacos , Animales , Animales Modificados Genéticamente , Sitios de Unión , Islas de CpG/efectos de los fármacos , Metilación de ADN/efectos de los fármacos , Proteína p300 Asociada a E1A/fisiología , Embrión no Mamífero/efectos de los fármacos , Genes Reporteros , Histonas/metabolismo , Humanos , Ratones , Naloxona/farmacología , Proteína Homeótica Nanog/biosíntesis , Proteína Homeótica Nanog/genética , Nestina/genética , Células-Madre Neurales/metabolismo , Factor 3 de Transcripción de Unión a Octámeros/biosíntesis , Factor 3 de Transcripción de Unión a Octámeros/genética , Procesamiento Proteico-Postraduccional/efectos de los fármacos , Factores de Transcripción SOX/biosíntesis , Factores de Transcripción SOX/genética , Regulación hacia Arriba/efectos de los fármacos , Proteínas de Pez Cebra/biosíntesis , Proteínas de Pez Cebra/genética
8.
Nat Commun ; 8(1): 728, 2017 09 28.
Artículo en Inglés | MEDLINE | ID: mdl-28959017

RESUMEN

Bilateral symmetry is a striking feature of the vertebrate body plan organization. Vertebral precursors, called somites, provide one of the best illustrations of embryonic symmetry. Maintenance of somitogenesis symmetry requires retinoic acid (RA) and its coactivator Rere/Atrophin2. Here, using a proteomic approach we identify a protein complex, containing Wdr5, Hdac1, Hdac2 and Rere (named WHHERE), which regulates RA signaling and controls embryonic symmetry. We demonstrate that Wdr5, Hdac1, and Hdac2 are required for RA signaling in vitro and in vivo. Mouse mutants for Wdr5 and Hdac1 exhibit asymmetrical somite formation characteristic of RA-deficiency. We also identify the Rere-binding histone methyltransferase Ehmt2/G9a, as a RA coactivator controlling somite symmetry. Upon RA treatment, WHHERE and Ehmt2 become enriched at RA target genes to promote RNA polymerase II recruitment. Our work identifies a protein complex linking key epigenetic regulators acting in the molecular control of embryonic bilateral symmetry.Retinoic acid (RA) regulates the maintenance of somitogenesis symmetry. Here, the authors use a proteomic approach to identify a protein complex of Wdr5, Hdac1, Hdac2 that act together with RA and coactivator Rere/Atrophin2 and a histone methyltransferase Ehmt2 to regulate embryonic symmetry.


Asunto(s)
Embrión de Mamíferos/metabolismo , Desarrollo Embrionario , Tretinoina/fisiología , Animales , Proteína p300 Asociada a E1A/genética , Proteína p300 Asociada a E1A/metabolismo , Proteína p300 Asociada a E1A/fisiología , Embrión de Mamíferos/citología , Epigénesis Genética , Histona Desacetilasa 1/genética , Histona Desacetilasa 1/metabolismo , Histona Desacetilasa 1/fisiología , Histona Desacetilasa 2/genética , Histona Desacetilasa 2/metabolismo , Histona Desacetilasa 2/fisiología , N-Metiltransferasa de Histona-Lisina/genética , N-Metiltransferasa de Histona-Lisina/metabolismo , N-Metiltransferasa de Histona-Lisina/fisiología , Histonas/química , Histonas/metabolismo , Péptidos y Proteínas de Señalización Intracelular , Ratones , Ratones Transgénicos , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/metabolismo , Proteínas del Tejido Nervioso/fisiología , Proteínas/genética , Proteínas/metabolismo , Proteínas/fisiología , Proteómica , Proteínas Represoras/genética , Proteínas Represoras/metabolismo , Proteínas Represoras/fisiología , Transducción de Señal , Somitos/crecimiento & desarrollo , Somitos/metabolismo , Somitos/ultraestructura , Tretinoina/metabolismo
9.
Adv Exp Med Biol ; 978: 39-62, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28523540

RESUMEN

Rubinstein-Taybi syndrome (RSTS) is a rare genetic disorder in humans characterized by growth and psychomotor delay, abnormal gross anatomy, and mild to severe mental retardation (Rubinstein and Taybi, Am J Dis Child 105:588-608, 1963, Hennekam et al., Am J Med Genet Suppl 6:56-64, 1990). RSTS is caused by de novo mutations in epigenetics-associated genes, including the cAMP response element-binding protein (CREBBP), the gene-encoding protein referred to as CBP, and the EP300 gene, which encodes the p300 protein, a CBP homologue. Recent studies of the epigenetic mechanisms underlying cognitive functions in mice provide direct evidence for the involvement of nuclear factors (e.g., CBP) in the control of higher cognitive functions. In fact, a role for CBP in higher cognitive function is suggested by the finding that RSTS is caused by heterozygous mutations at the CBP locus (Petrij et al., Nature 376:348-351, 1995). CBP was demonstrated to possess an intrinsic histone acetyltransferase activity (Ogryzko et al., Cell 87:953-959, 1996) that is required for CREB-mediated gene expression (Korzus et al., Science 279:703-707, 1998). The intrinsic protein acetyltransferase activity in CBP might directly destabilize promoter-bound nucleosomes, facilitating the activation of transcription. Due to the complexity of developmental abnormalities and the possible genetic compensation associated with this congenital disorder, however, it is difficult to establish a direct role for CBP in cognitive function in the adult brain. Although aspects of the clinical presentation in RSTS cases have been extensively studied, a spectrum of symptoms found in RSTS patients can be accessed only after birth, and, thus, prenatal genetic tests for this extremely rare genetic disorder are seldom considered. Even though there has been intensive research on the genetic and epigenetic function of the CREBBP gene in rodents, the etiology of this devastating congenital human disorder is largely unknown.


Asunto(s)
Proteína de Unión a CREB/fisiología , Proteína p300 Asociada a E1A/fisiología , Epigénesis Genética/genética , Histona Acetiltransferasas/fisiología , Código de Histonas/fisiología , Proteínas del Tejido Nervioso/fisiología , Procesamiento Proteico-Postraduccional/genética , Síndrome de Rubinstein-Taybi/genética , Acetilación , Animales , Encéfalo/metabolismo , Encéfalo/patología , Proteína de Unión a CREB/deficiencia , Proteína de Unión a CREB/genética , Cognición/fisiología , Modelos Animales de Enfermedad , Proteína p300 Asociada a E1A/deficiencia , Proteína p300 Asociada a E1A/genética , Regulación del Desarrollo de la Expresión Génica , Estudios de Asociación Genética , Histona Acetiltransferasas/deficiencia , Histona Acetiltransferasas/genética , Código de Histonas/genética , Inhibidores de Histona Desacetilasas/uso terapéutico , Humanos , Invertebrados/genética , Invertebrados/fisiología , Mamíferos/genética , Mamíferos/fisiología , Memoria/fisiología , Modelos Neurológicos , Mutación , Proteínas del Tejido Nervioso/deficiencia , Proteínas del Tejido Nervioso/genética , ARN Largo no Codificante/genética , Síndrome de Rubinstein-Taybi/metabolismo
10.
Int J Hematol ; 106(2): 269-281, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28378055

RESUMEN

ZNF384-related fusion genes are associated with a distinct subgroup of B-cell precursor acute lymphoblastic leukemias in childhood, with a frequency of approximately 3-4%. We previously identified a novel EP300-ZNF384 fusion gene. Patients with the ZNF384-related fusion gene exhibit a hematopoietic stem cell (HSC) gene expression signature and characteristic immunophenotype with negative or low expression of CD10 and aberrant expression of myeloid antigens, such as CD33 and CD13. However, the molecular basis of this pathogenesis remains completely unknown. In the present study, we examined the biological effects of EP300-ZNF384 expression induced by retrovirus-mediated gene transduction in an REH B-cell precursor acute lymphoblastic leukemia cell line, and observed the acquisition of the HSC gene expression signature and an up-regulation of GATA3 gene expression, as assessed by microarray analysis. In contrast, the gene expression profile induced by wild-type ZNF384 in REH cells was significantly different from that by EP300-ZNF384 expression. Together with the results of reporter assays, which revealed the enhancement of GATA3-promoter activity by EP300-ZNF384 expression, these findings suggest that EP300-ZNF384 mediates GATA3 gene expression and may be involved in the acquisition of the HSC gene expression signature and characteristic immunophenotype in B-cell precursor acute lymphoblastic leukemia cells.


Asunto(s)
Proteína p300 Asociada a E1A/genética , Factor de Transcripción GATA3/genética , Regulación del Desarrollo de la Expresión Génica/genética , Expresión Génica/genética , Fusión Génica/genética , Células Madre Hematopoyéticas , Leucemia de Células B/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Transactivadores/genética , Regulación hacia Arriba/genética , Línea Celular Tumoral , Niño , Proteína p300 Asociada a E1A/fisiología , Fusión Génica/fisiología , Humanos , Leucemia de Células B/inmunología , Leucemia-Linfoma Linfoblástico de Células Precursoras/inmunología , Transactivadores/fisiología
11.
Leukemia ; 31(6): 1382-1390, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-27881875

RESUMEN

The role that changes in DNA methylation and histone modifications have in human malignancies is poorly understood. p300 and CREB-binding protein (CBP), two distinct but highly homologous lysine acetyltransferases, are mutated in several cancers, suggesting their role as tumor suppressors. In the current study, we found that deletion of p300, but not CBP, markedly accelerated the leukemogenesis ofNup98-HoxD13 (NHD13) transgenic mice, an animal model that phenotypically copies human myelodysplastic syndrome (MDS). p300 deletion restored the ability of NHD13 expressing hematopoietic stem and progenitor cells (HSPCs) to self-renew in vitro, and to expand in vivo, with an increase in stem cell symmetric self-renewal divisions and a decrease in apoptosis. Furthermore, loss of p300, but not CBP, promoted cytokine signaling, including enhanced activation of the MAPK and JAK/STAT pathways in the HSPC compartment. Altogether, our data indicate that p300 has a pivotal role in blocking the transformation of MDS to acute myeloid leukemia, a role distinct from that of CBP.


Asunto(s)
Modelos Animales de Enfermedad , Proteína p300 Asociada a E1A/fisiología , Células Madre Hematopoyéticas/patología , Leucemia Experimental/etiología , Síndromes Mielodisplásicos , Proteínas de Fusión Oncogénica/genética , Animales , Células Cultivadas , Femenino , Células Madre Hematopoyéticas/metabolismo , Humanos , Leucemia Experimental/metabolismo , Leucemia Experimental/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Transducción de Señal
12.
Cancer Res ; 76(14): 4259-4269, 2016 07 15.
Artículo en Inglés | MEDLINE | ID: mdl-27261507

RESUMEN

The hypoxia-inducible transcription factor HIF1α drives expression of many glycolytic enzymes. Here, we show that hypoxic glycolysis, in turn, increases HIF1α transcriptional activity and stimulates tumor growth, revealing a novel feed-forward mechanism of glycolysis-HIF1α signaling. Negative regulation of HIF1α by AMPK1 is bypassed in hypoxic cells, due to ATP elevation by increased glycolysis, thereby preventing phosphorylation and inactivation of the HIF1α transcriptional coactivator p300. Notably, of the HIF1α-activated glycolytic enzymes we evaluated by gene silencing, aldolase A (ALDOA) blockade produced the most robust decrease in glycolysis, HIF-1 activity, and cancer cell proliferation. Furthermore, either RNAi-mediated silencing of ALDOA or systemic treatment with a specific small-molecule inhibitor of aldolase A was sufficient to increase overall survival in a xenograft model of metastatic breast cancer. In establishing a novel glycolysis-HIF-1α feed-forward mechanism in hypoxic tumor cells, our results also provide a preclinical rationale to develop aldolase A inhibitors as a generalized strategy to treat intractable hypoxic cancer cells found widely in most solid tumors. Cancer Res; 76(14); 4259-69. ©2016 AACR.


Asunto(s)
Fructosa-Bifosfato Aldolasa/antagonistas & inhibidores , Glucólisis , Subunidad alfa del Factor 1 Inducible por Hipoxia/fisiología , Neoplasias/tratamiento farmacológico , Transducción de Señal/fisiología , Proteínas Quinasas Activadas por AMP/fisiología , Animales , Hipoxia de la Célula , Línea Celular Tumoral , Proteína p300 Asociada a E1A/fisiología , Humanos , Ratones , Neoplasias/metabolismo , Ensayos Antitumor por Modelo de Xenoinjerto
13.
Exp Cell Res ; 342(1): 32-8, 2016 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-26921506

RESUMEN

p300 is a multifunctional transcriptional coactivator that interacts with numerous transcription factors and exhibits protein/histone acetyltransferase activity. Loss of p300 function in humans and in mice leads to craniofacial defects. In this study, we demonstrated that inhibition of p300 histone acetyltransferase activity with the compound, C646, altered the expression of several genes, including Cdh1 (E-cadherin) in mouse maxillary mesenchyme cells, which are the cells that give rise to the secondary palate. The increased expression of plasma membrane-bound E-cadherin was associated with reduced cytosolic ß-catenin, that led to attenuated signaling through the canonical Wnt pathway. Furthermore, C646 reduced both cell proliferation and the migratory ability of these cells. These results suggest that p300 histone acetyltransferase activity is critical for Wnt-dependent palate mesenchymal cell proliferation and migration, both processes that play a significant role in morphogenesis of the palate.


Asunto(s)
Cadherinas/metabolismo , Proteína p300 Asociada a E1A/fisiología , Vía de Señalización Wnt , Animales , Benzoatos/farmacología , Cadherinas/genética , Movimiento Celular , Células Cultivadas , Proteína p300 Asociada a E1A/antagonistas & inhibidores , Inhibidores Enzimáticos/farmacología , Femenino , Expresión Génica , Regulación del Desarrollo de la Expresión Génica , Técnicas de Silenciamiento del Gen , Histonas/metabolismo , Masculino , Mesodermo/citología , Mesodermo/embriología , Ratones Endogámicos ICR , Morfogénesis , Nitrobencenos , Hueso Paladar/citología , Hueso Paladar/embriología , Hueso Paladar/metabolismo , Pirazoles/farmacología , Pirazolonas , beta Catenina/metabolismo
14.
J Biol Chem ; 291(12): 6569-82, 2016 Mar 18.
Artículo en Inglés | MEDLINE | ID: mdl-26833564

RESUMEN

Maintenance of stem/progenitor cell-progeny relationships is required for tissue homeostasis during normal turnover and repair. Wnt signaling is implicated in both maintenance and differentiation of adult stem/progenitor cells, yet how this pathway serves these dichotomous roles remains enigmatic. We previously proposed a model suggesting that specific interaction of ß-catenin with either of the homologous Kat3 co-activators, p300 or CREB-binding protein, differentially regulates maintenance versus differentiation of embryonic stem cells. Limited knowledge of endogenous mechanisms driving differential ß-catenin/co-activator interactions and their role in adult somatic stem/progenitor cell maintenance versus differentiation led us to explore this process in defined models of adult progenitor cell differentiation. We focused primarily on alveolar epithelial type II (AT2) cells, progenitors of distal lung epithelium, and identified a novel axis whereby WNT5a/protein kinase C (PKC) signaling regulates specific ß-catenin/co-activator interactions to promote adult progenitor cell differentiation. p300/ß-catenin but not CBP/ß-catenin interaction increases as AT2 cells differentiate to a type I (AT1) cell-like phenotype. Additionally, p300 transcriptionally activates AT1 cell-specific gene Aqp-5. IQ-1, a specific inhibitor of p300/ß-catenin interaction, prevents differentiation of not only primary AT2 cells, but also tracheal epithelial cells, and C2C12 myoblasts. p300 phosphorylation at Ser-89 enhances p300/ß-catenin interaction, concurrent with alveolar epithelial cell differentiation. WNT5a, a traditionally non-canonical WNT ligand regulates Ser-89 phosphorylation and p300/ß-catenin interactions in a PKC-dependent manner, likely involving PKCζ. These studies identify a novel intersection of canonical and non-canonical Wnt signaling in adult progenitor cell differentiation that has important implications for targeting ß-catenin to modulate adult progenitor cell behavior in disease.


Asunto(s)
Células Madre Adultas/fisiología , Diferenciación Celular , Proteína p300 Asociada a E1A/fisiología , Proteína Quinasa C/metabolismo , Proteínas Wnt/metabolismo , beta Catenina/fisiología , Células Epiteliales Alveolares/fisiología , Animales , Acuaporina 5/genética , Acuaporina 5/metabolismo , Línea Celular , Impedancia Eléctrica , Expresión Génica , Ratones , Ratones Noqueados , Fosforilación , Regiones Promotoras Genéticas , Procesamiento Proteico-Postraduccional , Ratas , Vía de Señalización Wnt , Proteína Wnt-5a
15.
Int Endod J ; 48(10): 976-85, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25288362

RESUMEN

AIM: To investigate the role of p300 in the regulation of proliferation and odontogenic differentiation of human dental pulp cells (HDPCs). METHODOLOGY: The recombinant lentiviral vector pshRNA-copGFP was used to knock-down p300 expression in HDPCs. Protein level of acetylated H3 was detected. The proliferation of HDPCs was measured using the CCK8 assay. The cell cycle and apoptosis were analysed using flow cytometry and TUNEL staining, respectively. The expression levels of Cdc25A, p21(waf1) and the cleaved products of caspase 3 and caspase 7 were determined utilizing real-time quantitative polymerase chain reaction and Western blotting analysis. The alkaline phosphatase (ALP) activity was measured, and the formation of mineralized nodules was assessed using alizarin red staining after the induction of odontogenic differentiation of HDPCs. The expression levels of the odontogenic differentiation markers DMP-1, DSPP and DSP were detected utilizing real-time quantitative polymerase chain reaction and Western blotting analysis. RESULTS: After p300 was knocked down in HDPCs, p300 was significantly down-regulated at both the mRNA and protein levels, and histone H3 acetylation was reduced. The proliferation capacity of HDPCs was suppressed in p300 knock-down groups. The cells were arrested in the G0/G1 phase of the cell cycle, and cell apoptosis was triggered. ALP activity, the formation of mineralized nodules and the expression levels of DMP-1, DSPP and DSP were all decreased in p300-knock-down HDPCs undergoing odontogenic differentiation. CONCLUSION: Knocking down p300 restrains the proliferation and odontogenic differentiation potentiality of HDPCs.


Asunto(s)
Ciclo Celular/fisiología , Pulpa Dental/citología , Proteína p300 Asociada a E1A/fisiología , Odontogénesis/fisiología , Adolescente , Adulto , Fosfatasa Alcalina/metabolismo , Apoptosis , Biomarcadores/metabolismo , Western Blotting , Diferenciación Celular/fisiología , Proliferación Celular/fisiología , Proteína p300 Asociada a E1A/metabolismo , Proteínas de la Matriz Extracelular/metabolismo , Citometría de Flujo , Humanos , Etiquetado Corte-Fin in Situ , Técnicas In Vitro , Fosfoproteínas/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Sialoglicoproteínas/metabolismo
16.
Tumour Biol ; 35(8): 7499-504, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24789432

RESUMEN

The objective of this study was to investigate the mechanism of midazolam in inhibiting the proliferation of hypopharyngeal squamous carcinoma cells. Cultured FaDu cancer cells were treated with different concentrations of midazolam. MTT and BrdU incorporation assays were then used to evaluate cancer cell proliferation. The mRNA and protein levels of p300, a key factor involved in the tumorigenesis of numerous cancers, were measured with RT-PCR and Western blotting, respectively. Midazolam inhibited the expression of p300 and the proliferation of FaDu cells. Additionally, knockdown of p300 resulted in increased expression of p21 and p27 and decreased expression of p-Rb while inhibiting the proliferation of FaDu cells. Midazolam inhibits the proliferation of human head and neck squamous carcinoma cells by downregulating p300. Midazolam may be useful for the treatment of hypopharyngeal squamous cancers.


Asunto(s)
Carcinoma de Células Escamosas/tratamiento farmacológico , Proliferación Celular/efectos de los fármacos , Proteína p300 Asociada a E1A/fisiología , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Neoplasias Hipofaríngeas/tratamiento farmacológico , Midazolam/farmacología , Carcinoma de Células Escamosas/patología , Regulación hacia Abajo , Proteína p300 Asociada a E1A/antagonistas & inhibidores , Neoplasias de Cabeza y Cuello/patología , Humanos , Neoplasias Hipofaríngeas/patología , Proteína de Retinoblastoma/fisiología , Carcinoma de Células Escamosas de Cabeza y Cuello , Células Tumorales Cultivadas
17.
Stem Cells ; 32(7): 1805-16, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24648406

RESUMEN

Master transcription factors Oct4, Sox2, and Nanog are required to maintain the pluripotency and self-renewal of embryonic stem cells (ESCs) by regulating a specific transcriptional network. A few other transcription factors have been shown to be important in ESCs by interacting with these master transcription factors; however, little is known about the transcriptional mechanisms regulated by coregulators (coactivators and corepressors). In this study, we examined the function of two highly homologous coactivators, p300 and CREB-binding protein (CBP), in ESCs. We find that these two coactivators play redundant roles in maintaining the undifferentiated state of ESCs. They are recruited by Nanog through physical interaction to Nanog binding loci, mediating the formation of long-range chromatin looping structures, which is essential to maintain ESC-specific gene expression. Further functional studies reveal that the p300/CBP binding looping fragments contain enhancer activities, suggesting that the formation of p300/CBP-mediated looping structures may recruit distal enhancers to create a concentration of factors for the transcription activation of genes that are involved in self-renewal and pluripotency. Overall, these results provide a total new insight into the transcriptional regulation mechanism of coactivators p300 and CBP in ESCs, which is important in maintaining self-renewal and pluripotency, by mediating the formation of higher order chromosome structures.


Asunto(s)
Proteína de Unión a CREB/fisiología , Cromatina/genética , Proteína p300 Asociada a E1A/fisiología , Células Madre Embrionarias/metabolismo , Animales , Sitios de Unión , Diferenciación Celular , Células Cultivadas , Ensamble y Desensamble de Cromatina , Epistasis Genética , Humanos , Ratones , Familia de Multigenes , Conformación de Ácido Nucleico , Unión Proteica , Estructura Terciaria de Proteína , Activación Transcripcional
18.
Nucleic Acids Res ; 41(22): 10199-214, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24038357

RESUMEN

Lens induction is a classical embryologic model to study cell fate determination. It has been proposed earlier that specific changes in core histone modifications accompany the process of cell fate specification and determination. The lysine acetyltransferases CBP and p300 function as principal enzymes that modify core histones to facilitate specific gene expression. Herein, we performed conditional inactivation of both CBP and p300 in the ectodermal cells that give rise to the lens placode. Inactivation of both CBP and p300 resulted in the dramatic discontinuation of all aspects of lens specification and organogenesis, resulting in aphakia. The CBP/p300(-/-) ectodermal cells are viable and not prone to apoptosis. These cells showed reduced expression of Six3 and Sox2, while expression of Pax6 was not upregulated, indicating discontinuation of lens induction. Consequently, expression of αB- and αA-crystallins was not initiated. Mutant ectoderm exhibited markedly reduced levels of histone H3 K18 and K27 acetylation, subtly increased H3 K27me3 and unaltered overall levels of H3 K9ac and H3 K4me3. Our data demonstrate that CBP and p300 are required to establish lens cell-type identity during lens induction, and suggest that posttranslational histone modifications are integral to normal cell fate determination in the mammalian lens.


Asunto(s)
Proteína de Unión a CREB/fisiología , Proteína p300 Asociada a E1A/fisiología , Histonas/metabolismo , Cristalino/embriología , Acetilación , Animales , Apoptosis , Proteína de Unión a CREB/genética , Proteína p300 Asociada a E1A/genética , Inducción Embrionaria , Expresión Génica , Cristalino/anatomía & histología , Cristalino/enzimología , Ratones , Mutación , Procesamiento Proteico-Postraduccional , Fase S
19.
Cardiovasc Toxicol ; 13(4): 316-22, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23632743

RESUMEN

Histone acetylase (HAT) p300 plays an important role in the regulation of cardiac gene expression. During cardiac development, bone morphogenetic protein (BMP)-2 induces the expression of cardiac transcription factors. However, the underlying molecular mechanism(s) is not clear. In the present study, we tested the hypothesis that p300-mediated histone acetylation was essential for the regulation of cardiac transcription factors by BMP2. Cultured rat H9c2 embryonic cardiac myocytes (H9c2 cells) were transfected with recombinant adenoviruses expressing human BMP2 (AdBMP2) with or without curcumin, a specific p300-HAT inhibitor. Quantitative real-time RT-PCR analysis showed that curcumin substantially inhibited both AdBMP2-induced and basal expression levels of cardiac transcription factors GATA4 and MEF2C, but not Tbx5. Similarly, chromatin immunoprecipitation (ChIP) analysis showed that curcumin inhibited both AdBMP2-induced and basal histone H3 acetylation levels in the promoter regions of GATA4 and MEF2C, but not of Tbx5. In addition, curcumin selectively suppressed AdBMP2-induced expression of HAT p300, but not HAT GCN5 in H9c2 cells. The data indicated that inhibition of histone H3 acetylation with curcumin diminished BMP2-induced expression of GATA4 and MEF2C, suggesting that p300-mediated histone acetylation was essential for the regulation of GATA4 and MEF2C by BMP2 in H9c2 cells.


Asunto(s)
Proteína Morfogenética Ósea 2/antagonistas & inhibidores , Proteína Morfogenética Ósea 2/biosíntesis , Proteína p300 Asociada a E1A/fisiología , Factor de Transcripción GATA4/fisiología , Histonas/antagonistas & inhibidores , Acetilación/efectos de los fármacos , Animales , Células Cultivadas , Curcumina/farmacología , Factor de Transcripción GATA4/antagonistas & inhibidores , Histonas/metabolismo , Humanos , Factores de Transcripción MEF2/antagonistas & inhibidores , Factores de Transcripción MEF2/fisiología , Ratas , Transfección/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...